Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Neoplasm
100%
Lung Cancer
89%
Cancer
69%
Positron Emission Tomography-Computed Tomography
51%
Metastatic Carcinoma
50%
Magnetic Resonance Imaging
48%
Diseases
45%
Non Small Cell Lung Cancer
45%
Computer Assisted Tomography
44%
Malignant Neoplasm
37%
Radiation Therapy
33%
Mediastinum Mass
32%
Immunotherapy
31%
Lung
31%
Chest
27%
Diagnosis
25%
Thoracic Wall
23%
Radiology
20%
Biopsy Technique
20%
Esophageal Adenocarcinoma
20%
Differential Diagnosis
19%
Targeted Therapy
18%
Chemoradiotherapy
18%
Immune Checkpoint Inhibitor
17%
Thorax Radiography
17%
Pleura Mesothelioma
16%
Primary Tumor
16%
Arm
16%
Progression Free Survival
15%
positron emission tomographic scan
15%
Overall Survival
14%
Polyethylene Terephthalate
14%
Cross-Sectional Imaging
14%
Immunity
13%
Recurrent Disease
13%
Awareness
13%
Melanoma
13%
Nivolumab
13%
Silo-Filler's Disease
13%
Ipilimumab
13%
Thymus Cancer
12%
Patient Care
12%
Clinician
12%
Solid Malignant Neoplasm
12%
Treatment Response
12%
Selinexor
12%
Phase II Trials
12%
Incidental Finding
12%
Fluorodeoxyglucose F 18
11%
Thoracic Cancer
11%
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
61%
Lung Cancer
51%
Magnetic Resonance Imaging
37%
Tumor
32%
Radiologists
30%
Computed Tomography
28%
Selinexor
28%
Multi-arm
24%
Single Center
24%
Programmed Death-ligand 1 (PD-L1)
24%
Advanced Solid Tumors
24%
Radiation Therapy
23%
Positron Emission Tomography-computed Tomography (PET-CT)
20%
Phase Ib Study
20%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
19%
Imaging Modalities
19%
Immune Checkpoint Inhibitors
19%
Lung
18%
Metastatic Disease
17%
Metastasis
17%
Esophageal Adenocarcinoma
16%
Targeted Therapy
16%
Chemotherapy
16%
Phase II Trial
16%
Metastatic Tumor
16%
ACR Appropriateness Criteria
16%
Imaging Findings
15%
International Thymic Malignancy Interest Group (ITMIG)
15%
Thorax
15%
Response Evaluation Criteria in Solid Tumors (RECIST)
14%
Ipilimumab
13%
Mediastinal Mass
13%
Malignant Pleural Mesothelioma
13%
Carboplatin
12%
Nivolumab
12%
Median Progression-free Survival
12%
Mediastinal Compartments
12%
Clinical Outcomes
12%
Thymic Epithelial Neoplasm
12%
Advanced or Metastatic
12%
Thoracic CT
12%
Chemoradiation
12%
Incidental
12%
Paclitaxel
12%
Investigational New Drug
12%
Neoplasms
11%
Progression-free Survival
11%
Overall Survival
11%
Imaging Studies
11%
Phase II Study
10%